Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross, Anthony P. Bossis, Jeffrey R. Guss, Gabrielle Agin-Liebes, Tara C. Malone, Barry H Cohen, Sarah E. Mennenga, Alexander Belser, Krystallia Kalliontzi, James S. Babb, Patricia M A Corby, Brian L. Schmidt
Journal of Psychopharmacology · 2016 · 1,813 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Ross, S., Bossis, A. P., Guss, J. R., Agin-Liebes, G., Malone, T. C., Cohen, B. H., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J. S., Su, Z., Corby, P. M. A., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512
In text: (Ross et al., 2016)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. METHODS: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were randomly assigned and received treatment with single-dose psilocybin (0.3 mg/kg) or niacin, both in conjunction with psychotherapy. The primary outcomes were anxiety and depression assessed between groups prior to the crossover at 7 weeks. RESULTS: Prior to the crossover, psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life. At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60-80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression. CONCLUSIONS: In conjunction with psychotherapy, single moderate-dose psilocybin produced rapid, robust and enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00957359.
Related papers
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology1993
- TARGET ARTICLE: "Posttraumatic Growth: Conceptual Foundations and Empirical Evidence"2004
- The Posttraumatic Growth Inventory: Measuring the positive legacy of trauma1996
- Optimism, coping, and health: Assessment and implications of generalized outcome expectancies.1985
- The Fatigue Severity Scale1989
Metadata from OpenAlex (CC0). Citations are generated from the published record.